BLTE

Belite Bio, Inc. ADR (BLTE) | Rumor.io

Belite Bio

BLTE

Attention (50-day avg)0%

Attention rank (50-day avg)#1,434

Bullish sentiment (50-day avg)100%

Price to earnings ratio-71.8

Market capitalization6.7B

Earnings per share-2.74

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-77.6M

Social

What share of all stock conversation is about BLTE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Sep 4

Canaccord initiated coverage of BLTE with a Buy rating and $303 price target, citing tinlarebant as the first drug to slow Stargardt lesion growth.
Belite Bio's stock price has risen significantly, with a +13% gain on the day and a +25% gain over the last few days.
The company's largest shareholder, Darwin, has a $450mm position in BLTE and has been successful in identifying high-probability M&A candidates in the past.

Generated by AI

Sentiment

Of the messages about BLTE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	90.97% -7.73
Bearish	—	—	0% 0	9.03% +7.73

May 3

$BLTE has already hit its target price of $15 and could reach $17 or $20.
The stock's low float and low volume make it a prime candidate for a significant price increase.
The company's recent news, including Fast Track Designation, has the potential to send the stock price skyrocketing to $20 or even $30.

Generated by AI

Topics

Of the messages about BLTE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	50%	50.94%	75.29%
Analysts	0%	0%	43.4%	9.38%
Technical Analysis	0%	0%	3.77%	3.17%
Earnings	0%	0%	0%	7.48%
Controversies	50%	50%	1.89%	1.77%
Macro	0%	0%	0%	2.92%

Dec 1

Belite Bio's ($BLTE) Phase 3 DRAGON trial of Tinlarebant achieved a statistically significant p-value of 0.0033, demonstrating clinical efficacy in treating Stargardt disease.
The positive topline results from the trial have sparked a surge in Belite Bio's shares, with some analysts issuing buy recommendations and price targets.
The trial's success marks a historic breakthrough for Stargardt disease treatment, offering new hope for people living with the previously untreatable condition.

Generated by AI

Community

Of the messages about BLTE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	97.5%	73.98%	70.78%
Newcomers	100%	2.5%	26.02%	29.22%

Regulars· Dec 1

Belite Bio's Tinlarebant has demonstrated clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033.
The drug has met its primary efficacy endpoint, offering new hope for people living with a disease once deemed untreatable, and analysts are positive, with HC Wainwright issuing a Buy recommendation.
Belite Bio's stock has surged as a result of the positive topline results, with the company's market cap increasing, and analysts are now targeting a price of $128.17, with a recent price of $139.63.

Newcomers· Dec 1

Belite Bio's oral drug for Stargardt disease hits main goal in pivotal trial, significantly reducing lesion growth.
Belite Bio's positive Phase 3 results for its Stargardt disease treatment, tinlarebant, show a 40% editing rate in NHP, indicating a clear path forward for the company.
Belite Bio's Stargardt disease treatment, tinlarebant, shows a statistically significant reduction in retinal lesion growth versus placebo in a pivotal Phase 3 trial, paving the way for regulatory filings.

Generated by AI

News

Belite Bio at H.C. Wainwright conference: tinlarebant nears FDA review

14d agoinvesting.com

Belite Bio at Cantor healthcare conference: tinlarebant advances

18d agoInvesting.com

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)

Tipranks Press Release.

20d agoThe Globe and Mail

Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs

20d agoInvesting.com

Belite Bio CEO Lin Yu-Hsin sells $19.08m in company shares

20d agoInvesting.com

Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

20d agoYahoo Finance

Also Discussed

Investors talking about BLTE also mention

#	Name	Attention
1	Tema Oncology ETFCANC	0%0
2	iShares ESG Aware MSCI EM ETFESGE	0%new
3	Tradr 2X Long SPY Quarterly ETFSPYQ	0%new
4	iShares MSCI Japan Value ETFEWJV	0%0
5	BFC Capital Trust II 7.20% Cumulative Trust Preferred SecuritiesBANFP	0%0
6	Defiance Oil Enhanced Options Income ETFUSOY	0.04%+0.01
7	GPGI IncCMPO	0%0
8	Pharvaris N.V. Ordinary SharesPHVS	0%0
9	RAPT - RAPT Therapeutics, Inc.	——
10	authID Inc.AUID	0%0

Belite Bio, Inc. ADR

Healthcare
Biotechnology

Belite Bio, Inc. ADR is a clinical-stage biopharmaceutical company focused on developing oral therapies for degenerative retinal diseases and selected metabolic disorders. Its lead candidate, Tinlarebant, is being studied for eye conditions such as Stargardt disease type 1 and geographic atrophy, with an emphasis on preserving retinal health and slowing disease progression. The company also develops LBS-009, a preclinical oral therapy aimed at metabolic diseases including liver disorders, type 2 diabetes, and gout. Belite Bio, Inc. ADR operates in the biotechnology and pharmaceuticals sector, where it contributes to the advancement of targeted treatments for conditions with significant unmet medical needs. The company is based in San Diego, California, and focuses on drug discovery and development centered on small-molecule therapeutics.

Website

Location

12750 High Bluff Drive

San Diego, CA, 92130

United States

Social

What share of all stock conversation is about BLTE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Sep 4

Canaccord initiated coverage of BLTE with a Buy rating and $303 price target, citing tinlarebant as the first drug to slow Stargardt lesion growth.
Belite Bio's stock price has risen significantly, with a +13% gain on the day and a +25% gain over the last few days.
The company's largest shareholder, Darwin, has a $450mm position in BLTE and has been successful in identifying high-probability M&A candidates in the past.

Generated by AI

Sentiment

Of the messages about BLTE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	90.97% -7.73
Bearish	—	—	0% 0	9.03% +7.73

May 3

$BLTE has already hit its target price of $15 and could reach $17 or $20.
The stock's low float and low volume make it a prime candidate for a significant price increase.
The company's recent news, including Fast Track Designation, has the potential to send the stock price skyrocketing to $20 or even $30.

Generated by AI

Topics

Of the messages about BLTE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	50%	50.94%	75.29%
Analysts	0%	0%	43.4%	9.38%
Technical Analysis	0%	0%	3.77%	3.17%
Earnings	0%	0%	0%	7.48%
Controversies	50%	50%	1.89%	1.77%
Macro	0%	0%	0%	2.92%

Dec 1

Belite Bio's ($BLTE) Phase 3 DRAGON trial of Tinlarebant achieved a statistically significant p-value of 0.0033, demonstrating clinical efficacy in treating Stargardt disease.
The positive topline results from the trial have sparked a surge in Belite Bio's shares, with some analysts issuing buy recommendations and price targets.
The trial's success marks a historic breakthrough for Stargardt disease treatment, offering new hope for people living with the previously untreatable condition.

Generated by AI

Community

Of the messages about BLTE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	97.5%	73.98%	70.78%
Newcomers	100%	2.5%	26.02%	29.22%

Regulars· Dec 1

Belite Bio's Tinlarebant has demonstrated clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033.
The drug has met its primary efficacy endpoint, offering new hope for people living with a disease once deemed untreatable, and analysts are positive, with HC Wainwright issuing a Buy recommendation.
Belite Bio's stock has surged as a result of the positive topline results, with the company's market cap increasing, and analysts are now targeting a price of $128.17, with a recent price of $139.63.

Newcomers· Dec 1

Belite Bio's oral drug for Stargardt disease hits main goal in pivotal trial, significantly reducing lesion growth.
Belite Bio's positive Phase 3 results for its Stargardt disease treatment, tinlarebant, show a 40% editing rate in NHP, indicating a clear path forward for the company.
Belite Bio's Stargardt disease treatment, tinlarebant, shows a statistically significant reduction in retinal lesion growth versus placebo in a pivotal Phase 3 trial, paving the way for regulatory filings.

Generated by AI

Belite Bio

Social

Sep 4

May 3

Dec 1

Regulars· Dec 1

Newcomers· Dec 1

Belite Bio at H.C. Wainwright conference: tinlarebant nears FDA review

Belite Bio at Cantor healthcare conference: tinlarebant advances

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)

Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs

Belite Bio CEO Lin Yu-Hsin sells $19.08m in company shares

Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross

Also Discussed

Belite Bio, Inc. ADR

Company Information

Location

Belite Bio at H.C. Wainwright conference: tinlarebant nears FDA review

Belite Bio at Cantor healthcare conference: tinlarebant advances

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)

Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs

Belite Bio CEO Lin Yu-Hsin sells $19.08m in company shares

Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross

Also Discussed

Social

Sep 4

May 3

Dec 1

Regulars· Dec 1

Newcomers· Dec 1